YEAR-END AND Q4 REPORT 2007 FROM SCN

Scandinavian Clinical Nutrition, listed on NGM Equity and Oslo Axess, today releases the year-end and Q4 interim report for 2007. The entire report can be found in the attached pdf file, and on the company’s website www.scnutrition.com.

2007 in brief (Group)

· Revenues for the period amounted to MSEK 16.2 (2.6)

· EBIT amounted to MSEK -61.3 (-21.2)

· Profit for the period amounted to MSEK -62.9 (-21.2)

· Earnings per share, basic and diluted, amounted to -6.05 SEK (-4.06)

· Listing on NGM Equity (SE) and Oslo Axess (NO)

· Strategic acquisition of the Danish biotech company Nordic Phytopharma A/S (now SCN Denmark A/S)

· 16 new contracts signed for Coldizin and Immulina world-wide

· Has entered US market with first of many products

· Goal: to launch two more products in USA in 2008 and add more markets for existing products

2007 has been a year of investments for SCN, in organization and infrastructure, in financial stability, in R&D and product development, and in the company’s R&D and sales partnerships. In addition to the key points mentioned above, the company has taken over all rights to the product CUUR on all markets world-wide, and also acquired two new products (Coldizin and Immulina) through the acquisition of Nordic Phytopharma A/S. SCN has also established a marketing organization on the Scandinavian market, signed license agreements for two new interesting substances, and carried on with the company’s R&D collaborations, primarily with Karolinska Institutet. SCN has also continued the US market venture, and since the sales figures for CUUR so far have been in line with expectations, the company aims to launch additional products in USA during 2008.

Financial calendar

SCN is intending to publish the Annual Report for 2007 on April 22, at the same time as the shareholders are sent the material for the Annual General Meeting, which will take place on May 22. The Annual Report, as well as the rest of the material, will be available on SCN’s website www.scnutrition.com. The interim reports for 2008 will as previously communicated be published on May 9 (Q1), August 22 (Q2) and November 7 (Q3).

The report in its entirety can be found in the attached pdf file, as well as on the company’s website, www.scnutrition.com.

More information:

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Thomas Christensen, CFO, tc@scnutrition.com, +47 922 55 444

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).